
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics demonstrates a promising financial outlook supported by its clinical-stage pipeline, particularly with the positive safety and efficacy data for Aucazyl, which shows potential to outperform competitors in the CAR-T space. The company is also positioned to achieve significant gross margins of 60-70% due to improvements in manufacturing processes and increased utilization. Furthermore, the anticipated long-term benefits of its therapies, as indicated by decreased exhaustion markers and the positive feedback from regulatory bodies, bolster the potential for sustained success in its cancer treatment strategies.
Bears say
Autolus Therapeutics's sales are anticipated to remain flat in Q3 2025 due to alterations in CMS reimbursement policies, casting uncertainty on future revenue growth. The company's production capacity of CAR-T therapeutics is projected to fall short of initial forecasts, which may hinder its ability to meet market demand. Additionally, the presence of significant adverse events associated with its therapies, such as cytokine release syndrome and neurotoxicity, raises concerns about their broader application and acceptance in the market.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares